Wockhardt Limited (WOCKPHARMA.NS)

INR 1453.5

(0.53%)

Market Cap (In INR)

236.14 Billion

Revenue (In INR)

27.89 Billion

Net Income (In INR)

-4.63 Billion

Avg. Volume

570.96 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
378.05-1536.6
PE
-
EPS
-
Beta Value
1.51
ISIN
INE049B01025
CUSIP
Y73505136
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Habil Fakhruddin Khorakiwala
Employee Count
-
Website
https://www.wockhardt.com
Ipo Date
2002-07-01
Details
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.